Literature DB >> 18987145

Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity.

Nadine Laguette1, Serge Benichou, Stéphane Basmaciogullari.   

Abstract

The viral protein Nef contributes to the optimal infectivity of human and simian immunodeficiency viruses. The requirement for Nef during viral biogenesis particles suggests that Nef might play a role in this process. Alternatively, because Nef is incorporated into viruses, it might play a role when progeny virions reach target cells. We challenged these hypotheses by manipulating the amounts of Nef incorporated in viruses while keeping its expression level constant in producer cells. This was achieved by forcing the incorporation of Nef into viral particles by fusing a Vpr sequence to the C-terminal end of Nef. A cleavage site for the viral protease was introduced between Nef and Vpr to allow the release of Nef fragments from the fusion protein during virus maturation. We show that the resulting Nef-CS-Vpr fusion partially retains the ability of Nef to downregulate cell surface CD4 and that high amounts of Nef-CS-Vpr are incorporated into viral particles compared with what is seen for wild-type Nef. The fusion protein is processed during virion maturation and releases Nef fragments similar to those found in viruses produced in the presence of wild-type Nef. Unlike viruses produced in the presence of wild-type Nef, viruses produced in the presence of Nef-CS-Vpr do not have an increase in infectivity and are as poorly infectious as viruses produced in the absence of Nef. These findings demonstrate that the presence of Nef in viral particles is not sufficient to increase human immunodeficiency virus type 1 infectivity and suggest that Nef plays a role during the biogenesis of viral particles.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18987145      PMCID: PMC2612363          DOI: 10.1128/JVI.01633-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  96 in total

1.  The effects of HIV-1 Nef on CD4 surface expression and viral infectivity in lymphoid cells are independent of rafts.

Authors:  Nathalie Sol-Foulon; Cécile Esnault; Yann Percherancier; Françoise Porrot; Patricia Metais-Cunha; Françoise Bachelerie; Olivier Schwartz
Journal:  J Biol Chem       Date:  2004-05-07       Impact factor: 5.157

2.  Nef enhances HIV-1 infectivity via association with the virus assembly complex.

Authors:  Mingli Qi; Christopher Aiken
Journal:  Virology       Date:  2008-01-14       Impact factor: 3.616

3.  Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells.

Authors:  Minoru Tobiume; Janet E Lineberger; Christopher A Lundquist; Michael D Miller; Christopher Aiken
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

4.  Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity.

Authors:  Edward M Campbell; Rafael Nunez; Thomas J Hope
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

5.  The importance of virus-associated host ICAM-1 in human immunodeficiency virus type 1 dissemination depends on the cellular context.

Authors:  Salim Bounou; Jean-François Giguere; Réjean Cantin; Caroline Gilbert; Michael Imbeault; Geneviève Martin; Michel J Tremblay
Journal:  FASEB J       Date:  2004-06-18       Impact factor: 5.191

6.  Novel (n)PKC kinases phosphorylate Nef for increased HIV transcription, replication and perinuclear targeting.

Authors:  Dietlinde Wolf; Simone I Giese; Vanessa Witte; Ellen Krautkrämer; Susanna Trapp; Gabriele Sass; Claudia Haller; Katja Blume; Oliver T Fackler; Andreas S Baur
Journal:  Virology       Date:  2007-09-29       Impact factor: 3.616

7.  HIV-1 Nef enhances both membrane expression and virion incorporation of Env products. A model for the Nef-dependent increase of HIV-1 infectivity.

Authors:  Ilaria Schiavoni; Susanna Trapp; Anna Claudia Santarcangelo; Valentina Piacentini; Katherina Pugliese; Andreas Baur; Maurizio Federico
Journal:  J Biol Chem       Date:  2004-03-19       Impact factor: 5.157

8.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.

Authors:  Ann M Sheehy; Nathan C Gaddis; Michael H Malim
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

9.  Recognition of dileucine-based sorting signals from HIV-1 Nef and LIMP-II by the AP-1 gamma-sigma1 and AP-3 delta-sigma3 hemicomplexes.

Authors:  Katy Janvier; Yukio Kato; Markus Boehm; Jeremy R Rose; José A Martina; Bong-Yoon Kim; Sundararajan Venkatesan; Juan S Bonifacino
Journal:  J Cell Biol       Date:  2003-12-22       Impact factor: 10.539

10.  Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.

Authors:  Paul R Gorry; Dale A McPhee; Erin Verity; Wayne B Dyer; Steven L Wesselingh; Jennifer Learmont; John S Sullivan; Michael Roche; John J Zaunders; Dana Gabuzda; Suzanne M Crowe; John Mills; Sharon R Lewin; Bruce J Brew; Anthony L Cunningham; Melissa J Churchill
Journal:  Retrovirology       Date:  2007-09-23       Impact factor: 4.602

View more
  21 in total

1.  Single-domain antibody-SH3 fusions for efficient neutralization of HIV-1 Nef functions.

Authors:  Jérôme Bouchet; Cécile Hérate; Carolin A Guenzel; Christel Vérollet; Annika Järviluoma; Julie Mazzolini; Salomeh Rafie; Patrick Chames; Daniel Baty; Kalle Saksela; Florence Niedergang; Isabelle Maridonneau-Parini; Serge Benichou
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

2.  Suboptimal provirus expression explains apparent nonrandom cell coinfection with HIV-1.

Authors:  Christelle Brégnard; Gregory Pacini; Olivier Danos; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

3.  HIV-1 Nef responsiveness is determined by Env variable regions involved in trimer association and correlates with neutralization sensitivity.

Authors:  Yoshiko Usami; Heinrich Göttlinger
Journal:  Cell Rep       Date:  2013-10-24       Impact factor: 9.423

4.  The Nef-like effect of murine leukemia virus glycosylated gag on HIV-1 infectivity is mediated by its cytoplasmic domain and depends on the AP-2 adaptor complex.

Authors:  Yoshiko Usami; Sergei Popov; Heinrich G Göttlinger
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

5.  Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120.

Authors:  Julie Matz; Pascal Kessler; Jérôme Bouchet; Olivier Combes; Oscar Henrique Pereira Ramos; Francis Barin; Daniel Baty; Loïc Martin; Serge Benichou; Patrick Chames
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

6.  MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1.

Authors:  Massimo Pizzato
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

7.  Dendritic cell-mediated HIV-1 infection of T cells demonstrates a direct relationship to plasma viral RNA levels.

Authors:  Reetakshi Arora; Lara Bull; Edward B Siwak; Rajesh Thippeshappa; Roberto C Arduino; Jason T Kimata
Journal:  J Acquir Immune Defic Syndr       Date:  2010-06       Impact factor: 3.731

Review 8.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

9.  The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor.

Authors:  Birthe Trautz; Virginia Pierini; Rebecka Wombacher; Bettina Stolp; Amanda J Chase; Massimo Pizzato; Oliver T Fackler
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

10.  Comparative proteomic analysis of HIV-1 particles reveals a role for Ezrin and EHD4 in the Nef-dependent increase of virus infectivity.

Authors:  Christelle Brégnard; Alessia Zamborlini; Marjorie Leduc; Philippe Chafey; Luc Camoin; Ali Saïb; Serge Benichou; Olivier Danos; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.